Table 2.

Descriptions of values and preferences studies

Study	Location	Population description	Study design	Methods	Sample size (n)
End users
Begnel et al24	Kenya: Homa Bay, Kisii, Kisumu, Migori, Nyamira, and Siaya	Adults aged 18+ years	Quantitative	Cross-sectional SMS survey	2498
Crawford et al26	USA: Atlanta area, Georgia	Adult MSM	Qualitative	Semi-structured in-depth interviews	8
Crawford et al25	USA: Atlanta, Georgia	HIV− MSM not using PrEP	Quantitative	Cross-sectional survey	259
Havens et al21	USA: Omaha, Nebraska	PrEP users	Quantitative	Cross-sectional survey in case study project	60
Lutz et al27	USA: Arizona	HIV− PrEP clients and HIV+ ART clients	Quantitative	Cross-sectional survey	49
Minnis et al28	South Africa: Nyanga and Masiphumelele, near Cape Town	PrEP-eligible youth aged 18–24 years	Quantitative	Discrete choice experiment	807
Zhu et al29	USA: Washington, District of Columbia and Maryland	HIV− adults	Quantitative	Cross-sectional survey	117
Pharmacists and other professional stakeholders
Broekhuis et al30	USA: Nebraska and Iowa	Pharmacists	Quantitative	Cross-sectional online survey	140
Crawford et al26	USA: Atlanta area, Georgia	Pharmacists	Qualitative	Semi-structured in-depth interviews	6
Havens et al21	USA: Omaha, Nebraska	Pharmacists	Quantitative	Cross-sectional survey in case study project	7
Hopkins et al31	USA: Atlanta, Georgia	Pharmacists and pharmacy technicians	Qualitative	Semi-structured in-depth interviews	13
Koester et al32	USA: California	Pharmacists, physicians, pharmacy representatives	Qualitative	Semi-structured phone interviews	11
Ortblad et al33	Kenya: Nairobi	Stakeholders from PrEP regulatory, professional, healthcare service delivery, civil society and research organisations	Qualitative	Focus groups	36

ART, antiretroviral therapy; MSM, men who have sex with men; PrEP, pre-exposure prophylaxis.